Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Impact and Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine on Population Incidence of Vaccine and Non-Vaccine Serotype Invasive Pneumococcal Disease in Blantyre, Malawi, 2006-2018: Prospective Observational Time-Series and Case-Control Studies
20 Pages Posted: 30 Dec 2020
More...Abstract
Background: Population impact of pneumococcal conjugate vaccines (PCV) depend on direct and indirect protection. Following Malawi’s 2011 introduction of the 13-valent PCV (PCV13), we examined impact on vaccine serotype (VT) and non-VT (NVT) invasive pneumococcal disease (IPD) among vaccine-age-eligible and vaccine-age-ineligible children and adults.
Methods: Laboratory-based surveillance at a government hospital in Malawi included 6 years before and 7 years after PCV13 introduction. Using negative-binomial regression, we evaluated secular trend-adjusted Incidence Rate Ratio (IRR) in VT- and NVT-IPD prior to and post PCV introduction. We compared predicted counterfactual incidence in hypothetical absence of vaccine with empirically observed incidence following vaccine introduction. A case-control study assessed vaccine effectiveness compared PCV uptake among vaccine-age-eligible IPD cases versus matched community controls.
Findings: Surveillance covered 10 281 476 person-years observation, with 140 498 blood and 63 291 cerebrospinal fluid cultures. IPD decline preceded PCV introduction. Compared to the counterfactually predicted incidence, post-vaccine VT-IPD incidence was 38% (95%CI: 37, 40) lower among infants, 74% (70, 78) among young children, 79% (76, 83) among older children and 47% (44, 51) among adolescents and adults. Though NVT-IPD has increased since 2015 , absolute rates remain low. The case-control study, (19 cases and 76 controls), showed vaccine effectiveness against VT-IPD of 80·7% (-73·7, 97·9).
Interpretation: Even with pre-existing declines, infant PCV13 introduction has led to substantial IPD reduction among vaccine-age-eligible children. However, seven years after PCV introduction, indirect effects benefitting unvaccinated infants and adults were more modest. Policy decisions should consider alternative strategies, including targeted vaccination outside infant EP to benefit vulnerable populations.
Funding Statement: This work was funded by Bill & Melinda Gates Foundation, USA (OPP117653) to RSH and a Wellcome Trust Programme Grant (WT091909/B/10/Z) to NF, NAC, RSH; National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government (Project number 16/136/46) to RSH. The MLW Clinical Research Programme is supported by a Strategic Award from the Wellcome Trust, UK (206545/Z/17/Z) to SG.
Declaration of Interests: NBZ, NAC & NF have received investigator-initiated research grants from GlaxoSmithKline Biologicals. NBZ & NAC received investigator-initiated research grants from Takeda Pharmaceuticals. NAC has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals. All other authors declare no competing interests.
Ethics Approval Statement: The study protocol was approved by Malawi’s National Health Sciences Research Committee (NHSRC; protocol 867), by the University of Malawi College of Medicine Research and Ethics Committee (COMREC; P.01/08/609 and P.09/09/826) and the University of Liverpool Research Ethics Committee (UoLREC; RETH490). The Centers for Disease Control and Prevention relied on the UoLREC for ethical approval. For the case-control component, the parent/guardian of all child participants provided written informed consent and, in addition, children 8 years or older provided written informed assent. This included consent for publication.
Suggested Citation: Suggested Citation